Novartis' Leqvio has potential to lead the cholesterol-lowering space

Swiss pharma giant Novartis (NOVN: VX) regained control of the cholesterol lowering drug Leqvio (inclisiran) in July 2021, cutting contractor Corden Pharma out of the loop in a bid to get the regulatory process back on the road, following a regulatory delay, and by December gained US Food and Drug Administration approval of the drug.

Now, pharma analytics firm GlobalData predicts that Leqvio sales may surpass those of Sanofi/Regeneron's Praluent (alirocumab) and Amgen's Repatha (evolocumab) by 2027 due to its administration convenience, according to GlobalData. The leading data and analytics company notes that Leqvio is in a better position compared to its competitors as it is administered by a healthcare professional twice per year, while Praluent and Repatha are injections that patients have to give themselves at home twice a month.

According to the analyst consensus forecasts from GlobalData’s Pharma Intelligence Center, Leqvio will reach $2.5 billion in sales by 2027, while Repatha and Praluent will reach $2.2 billion and $716 million, respectively.